1. Introduction/Overview Hematinics constitute a fundamental class of therapeutic agents essential for the synthesis of hemoglobin and the normal maturation of erythrocytes. These substances, primarily comprising iron, vitamin B12 (cobalamin), and folic acid, serve as critical substrates or cofactors in biochemical pathways governing erythropoiesis. Deficiencies in any one of these hematinic factors can lead to … Read more

1. Introduction/Overview The fibrinolytic system represents a crucial endogenous mechanism for the removal of intravascular fibrin clots, thereby maintaining vascular patency. Pharmacological modulation of this system constitutes a cornerstone in the management of thrombotic and hemorrhagic disorders. Fibrinolytic agents, commonly termed thrombolytics, are employed to dissolve pathological thrombi, while antifibrinolytic agents are utilized to inhibit … Read more

Introduction/Overview Antiplatelet drugs constitute a cornerstone of pharmacotherapy for the prevention and management of atherothrombotic events. These agents function by inhibiting platelet activation, adhesion, and aggregation, thereby impeding the formation of occlusive thrombi within the arterial circulation. The clinical significance of these drugs is underscored by their central role in reducing morbidity and mortality associated … Read more

Introduction/Overview The fibrinolytic system represents a critical endogenous mechanism for the removal of intravascular fibrin deposits, thereby maintaining vascular patency. Pharmacological modulation of this system constitutes a cornerstone in the management of thrombotic and hemorrhagic disorders. Fibrinolytic agents, often termed thrombolytics, are employed to dissolve pathological thrombi, while antifibrinolytic agents are utilized to inhibit excessive … Read more

1. Introduction/Overview Antiplatelet drugs constitute a cornerstone of pharmacotherapy for the prevention and treatment of arterial thrombotic events. These agents function by inhibiting platelet activation, adhesion, or aggregation, thereby impeding the formation of occlusive thrombi within the vasculature. The clinical significance of these drugs is substantial, given the global burden of atherosclerotic cardiovascular diseases, including … Read more

Introduction/Overview The management of dyslipidemia represents a cornerstone in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Hypolipidemic drugs, also termed lipid-lowering agents, comprise a diverse group of pharmacological interventions designed to modify circulating plasma lipid and lipoprotein concentrations. The clinical imperative for these agents stems from the established causal relationship between elevated levels … Read more

1. Introduction/Overview Dyslipidemia represents a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), a leading cause of global morbidity and mortality. The pharmacological management of dyslipidemia, primarily through the use of hypolipidemic drugs, constitutes a cornerstone of preventive cardiology. These agents target various components of lipid metabolism to reduce circulating levels of atherogenic lipoproteins, … Read more